Live Breaking News & Updates on Jesper Hallas

Stay updated with breaking news from Jesper hallas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses

Objective To investigate the comparative vaccine effectiveness of heterologous booster schedules (ie, three vaccine doses) compared with primary schedules (two vaccine doses) and with homologous mRNA vaccine booster schedules (three vaccine doses) during a period of omicron predominance.

Design Population based cohort analyses.

Setting Denmark, Finland, Norway, and Sweden, 27 December 2020 to 31 December 2022.

Participants All adults aged ≥18 years who had received at least a primary vaccination schedule of AZD1222 (Oxford-AstraZeneca) or monovalent SARS-CoV-2 wild type (ancestral) strain based mRNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), in any combination.

Main outcome measures The main outcome measure was country combined risks of covid-19 related hospital admission and death with covid-19 and additional outcomes of covid-19 related admission to an intensive care unit and SARS-CoV-2 infection. During a period of omicron predominance, ....

United Kingdom , Karolinska Institutet , Morten Andersen , Lars Christian Lund , Ulrike Baum , Coronavac Sinovac , Anders Hviid , Jostein Starrfelt , Eero Poukka , Jesper Hallas , Nicklas Pihlstr , Hinta Meijerink , S Janssen Johnson , Jesper Kj , Christian Holm Hansen , Mathijs Goossens , Catherine Cohet , Rickard Ljung , Emilia Myrup Thiesson , Mia Aakj , Pharmacovigilance Research Centre , Menarini Pharmaceuticals , Novo Nordisk , Sanofi Aventis , University Of Copenhagen , Finnish Medical Foundation ,